This review demonstrates improvements in glycated hemoglobin and body weight in patients, suggesting dual receptor agonists could transform cardiometabolic disease management.
Key Points
Dual glucagon and GLP-1 receptor agonists showed significant improvements in glycated hemoglobin levels and body weight.
Emerging evidence indicates these agents may enhance cardiovascular and renal outcomes in high-risk patients.
Clinical trials with survodutide and cotadutide outperform traditional therapies in efficacy metrics.
These next-generation treatments could redefine standards in precision medicine for metabolic diseases.